Literature DB >> 32075803

Cancer-associated fibroblasts promote immunosuppression by inducing ROS-generating monocytic MDSCs in lung squamous cell carcinoma.

Handan Xiang1, Carlo P Ramil2, Josephine Hai3, Chunsheng Zhang4, Huijun Wang5, Amanda A Watkins1, Roshi Afshar1, Peter Georgiev6, Marc A Sze7, Xuelei S Song3, Patrick J Curran3, Mangeng Cheng8, J Richard Miller3, Dongyu Sun3, Andrey Loboda9, Yanlin Jia1, Lily Y Moy3, An Chi10, Philip E Brandish11.   

Abstract

Cancer-associated fibroblasts (CAFs) represent a functionally heterogenous population of activated fibroblasts that constitutes a major component of tumor stroma. Although CAFs have been shown to promote tumor growth and mediate resistance to chemotherapy, the mechanisms by which they may contribute to immune suppression within the tumor microenvironment (TME) in lung squamous cell carcinoma (LSCC) remain largely unexplored. Here, we identified a positive correlation between CAF and monocytic myeloid cell abundances in 501 primary LSCCs by mining TCGA datasets. We further validated this finding in an independent cohort using imaging mass cytometry and found a significant spatial interaction between CAFs and monocytic myeloid cells in the TME. To delineate the interplay between CAFs and monocytic myeloid cells, we used chemotaxis assays to show that LSCC patient-derived CAFs promoted recruitment of CCR2+ monocytes via CCL2, which could be reversed by CCR2 inhibition. Using a three-dimensional culture system, we found that CAFs polarized monocytes to adopt a myeloid-derived suppressor cell (MDSC) phenotype, characterized by robust suppression of autologous CD8+ T-cell proliferation and IFNγ production. We further demonstrated that inhibiting IDO1 and NADPH oxidases, NOX2 and NOX4, restored CD8+ T-cell proliferation by reducing reactive oxygen species (ROS) generation in CAF-induced MDSCs. Taken together, our study highlights a pivotal role of CAFs in regulating monocyte recruitment and differentiation and demonstrated that CCR2 inhibition and ROS scavenging abrogate the CAF-MDSC axis, illuminating a potential therapeutic path to reversing the CAF-mediated immunosuppressive microenvironment.
Copyright ©2020, American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 32075803     DOI: 10.1158/2326-6066.CIR-19-0507

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  49 in total

Review 1.  Helicobacter pylori promotes gastric cancer progression through the tumor microenvironment.

Authors:  Linqi Zhu; Yue Huang; Hong Li; Shihe Shao
Journal:  Appl Microbiol Biotechnol       Date:  2022-06-20       Impact factor: 4.813

2.  Metabolic Interactions Between Tumor and Stromal Cells in the Tumor Microenvironment.

Authors:  Deepshikha Mishra; Debabrata Banerjee
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Characterization of the Tumor Immune Microenvironment in Lung Squamous Cell Carcinoma Using Imaging Mass Cytometry.

Authors:  Ran Li; Ying Lin; Yu Wang; Shaoyuan Wang; Yang Yang; Xinlin Mu; Yusheng Chen; Zhancheng Gao
Journal:  Front Oncol       Date:  2021-04-01       Impact factor: 6.244

Review 4.  The role of ROS in tumour development and progression.

Authors:  Eric C Cheung; Karen H Vousden
Journal:  Nat Rev Cancer       Date:  2022-01-31       Impact factor: 60.716

Review 5.  Modulation of the tumor microenvironment by natural agents: implications for cancer prevention and therapy.

Authors:  Haseeb Zubair; Mohammad Aslam Khan; Shashi Anand; Sanjeev Kumar Srivastava; Seema Singh; Ajay Pratap Singh
Journal:  Semin Cancer Biol       Date:  2020-05-26       Impact factor: 15.707

Review 6.  Tumor microenvironment: a prospective target of natural alkaloids for cancer treatment.

Authors:  Yanming Luo; Shuangshuang Yin; Jia Lu; Shiyue Zhou; Yingying Shao; Xiaomei Bao; Tao Wang; Yuling Qiu; Haiyang Yu
Journal:  Cancer Cell Int       Date:  2021-07-20       Impact factor: 5.722

Review 7.  Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer.

Authors:  Fanglong Wu; Jin Yang; Junjiang Liu; Ye Wang; Jingtian Mu; Qingxiang Zeng; Shuzhi Deng; Hongmei Zhou
Journal:  Signal Transduct Target Ther       Date:  2021-06-10

Review 8.  Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy.

Authors:  Mithunah Krishnamoorthy; Lara Gerhardt; Saman Maleki Vareki
Journal:  Cells       Date:  2021-05-11       Impact factor: 6.600

9.  A Novel Immune-Related Seventeen-Gene Signature for Predicting Early Stage Lung Squamous Cell Carcinoma Prognosis.

Authors:  Tao Fan; Zhiliang Lu; Yu Liu; Liyu Wang; He Tian; Yujia Zheng; Bo Zheng; Liyan Xue; Fengwei Tan; Qi Xue; Shugeng Gao; Chunxiang Li; Jie He
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561

Review 10.  From bench to bedside: Single-cell analysis for cancer immunotherapy.

Authors:  Emily F Davis-Marcisak; Atul Deshpande; Genevieve L Stein-O'Brien; Won J Ho; Daniel Laheru; Elizabeth M Jaffee; Elana J Fertig; Luciane T Kagohara
Journal:  Cancer Cell       Date:  2021-07-29       Impact factor: 38.585

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.